Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

Join Channel
Consolidated Standalone

Pfizer

₹4850 41.6 | 0.9%

Market Cap ₹22188 Cr.

Stock P/E 40.2

P/B -

Current Price ₹4850

Book Value ₹ 0

Face Value 10

52W High ₹6452.9

Dividend Yield 0.72%

52W Low ₹ 4050.1

Edit Ratio

Pfizer Research see more...

Overview Inc. Year: 1950Industry: Pharmaceuticals & Drugs

Pfizer Ltd is an India-based pharmaceutical agency. The Company has a portfolio of approximately 150 products across over 15 therapeutic areas. The Company is engaged in production, advertising, buying and selling and exporting pharmaceutical products. The Company gives various merchandise for anti-diabetic, erectile disorder, gastrointestinal (GI), multivitamins, anti-infectives, cardiovascular, dermatology, neurology, ache/fever/infection and autoimmune problems, amongst others. Its merchandise consist of Viagra, Daxid, Tricorex, Mucaine, Diamox, Hetrazan, Enbrel, Ativan, Pacitane, Folvite Tablets, Autrin Capsules, Prevenar 13, Wysolone, Loette, anti-infectives, cardiovascular, dermatology, Trulimax, Vibazime DT, Ovral G, Ovral L, Premarin pills, Premarin Vaginal Cream, Zosyn, Wymox, Tygacil, Cynomycin, Targit, Cyklokapron and Magnamycin. The Company has its personal production facility at Thane and Goa. The Company has numerous impartial settlement/third party manufacturers based throughout the country.

Read More..

Pfizer Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Pfizer Quarterly Results

#(Fig in Cr.)
Net Sales
Other Income
Total Income
Total Expenditure
Operating Profit
Interest
Depreciation
Exceptional Income / Expenses
Profit Before Tax
Provision for Tax
Profit After Tax
Adjustments
Profit After Adjustments
Adjusted Earnings Per Share

Pfizer Profit & Loss

#(Fig in Cr.) TTM
Net Sales
Other Income
Total Income
Total Expenditure
Operating Profit
Interest
Depreciation
Exceptional Income / Expenses
Profit Before Tax
Provision for Tax
Profit After Tax
Adjustments
Profit After Adjustments
Adjusted Earnings Per Share

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 0% 0% 0% 0%
Operating Profit CAGR 0% 0% 0% 0%
PAT CAGR 0% 0% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 15% -1% 3% 9%
ROE Average NA% NA% NA% NA%
ROCE Average NA% NA% NA% NA%

Pfizer Balance Sheet

#(Fig in Cr.)
Shareholder's Funds
Minority's Interest
Borrowings
Other Non-Current Liabilities
Total Current Liabilities
Total Liabilities
Fixed Assets
Other Non-Current Assets
Total Current Assets
Total Assets

Pfizer Cash Flow

#(Fig in Cr.)
Opening Cash & Cash Equivalents
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activities
Net Cash Inflow / Outflow
Closing Cash & Cash Equivalent

Pfizer Ratios

#
Earnings Per Share (Rs)
CEPS(Rs)
DPS(Rs)
Book NAV/Share(Rs)
Core EBITDA Margin(%)
EBIT Margin(%)
Pre Tax Margin(%)
PAT Margin (%)
Cash Profit Margin (%)
ROA(%)
ROE(%)
ROCE(%)
Receivable days
Inventory Days
Payable days
PER(x)
Price/Book(x)
Dividend Yield(%)
EV/Net Sales(x)
EV/Core EBITDA(x)
Net Sales Growth(%)
EBIT Growth(%)
PAT Growth(%)
EPS Growth(%)
Debt/Equity(x)
Current Ratio(x)
Quick Ratio(x)
Interest Cover(x)
Total Debt/Mcap(x)

Pfizer Shareholding Pattern

# Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Promoter 63.92 63.92 63.92 63.92 63.92 63.92 63.92 63.92 63.92 63.92
FII 2.55 2.55 2.77 2.8 2.81 2.82 3.03 3.32 3.22 3.54
DII 14.83 14.88 14.93 14.9 14.89 15.01 15.15 15.33 15.84 16.03
Public 18.7 18.65 18.38 18.38 18.38 18.25 17.9 17.42 17.02 16.5
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros